

European
Innovation
Council



EIC USA Soft-landing Programme for Health and Life Sciences

Catalogue



19 - 24 May 2024

San Francisco and Silicon Valley

 #EUeic
 @EUeic
 eic.ec.europa.eu



Contents

What is the European Innovation Council?.....	3
The EIC Fund.....	3
The EIC USA Soft-landing Programme.....	3
European Union Delegation - San Francisco Office.....	3
Meet the Founders.....	4
Meet the Team.....	9
Meet the Partners.....	10



1

What is the European Innovation Council?

With a 10.1 billion Euro budget, the European Innovation Council (EIC) is Europe's flagship innovation programme to identify, develop and scale up breakthrough technologies and game changing innovations. It provides support throughout the whole lifecycle of a company, from early-stage research to proof of concept, technology transfer and the financing and scale up of startups and small companies.

The EIC Fund

The EIC Fund is the 3 billion Euro investment branch of the EIC. It is Europe's largest investor for deep technologies, with a mission to invest across all European countries. The EIC focuses its investment in Health and Life Sciences and Clean Technologies. It is a part of a 95.5 billion Euro Horizon Europe initiative that aims to reach the U.N. sustainability goals by 2030.

The EIC Fund supports companies in the development and commercialization of disruptive technologies. It has an engaged network of capital providers and strategic partners to lead investment rounds or to co-invest with non-dilutive and equity funding. The investment stage is typically series A but the Fund may also participate in seed and growth rounds. The EIC is committed to the empowerment and support of female founders as well as the ambition to reduce the innovation divide among EU countries.

The EIC Soft-landing Programme

The EIC Soft-landing Programme aims to support EIC-backed companies in their commercialization strategy in international markets by opening business avenues through soft-landing activities, putting EU innovation under the spotlight in the world's most promising markets. Soft-landing activities provide a tailored introduction to the market, connecting founders with local experts, investors, partners and innovation supporting stakeholders that are fitted to their business. The EIC Soft-landing Programme will cover the following sectors: New Technologies/Industrial Technology; Health and Medical Care; Biotechnology and Pharma; and Clean Technologies/Energy.

European Union Delegation - San Francisco Office

The European Union Delegation's San Francisco Office serves as a vital diplomatic link between the European Union and the West Coast of the United States. Located in the heart of the vibrant tech and innovation hub, the office facilitates dialogue, cooperation, and partnerships between the EU, on the one hand, and California State and local officials, industry, academia, investors and a variety of stakeholder groups in the Bay Area and beyond, on the other. With a focus on fostering economic, cultural, and research exchanges, the office plays a crucial role in promoting EU values, policies, and initiatives. Through outreach programs, events, and collaborations, it aims to deepen understanding and strengthen ties between the EU and the diverse communities of San Francisco and beyond.

2 Meet the Founders

ABCDx

Barcelona, Spain
www.abcdx.ch



Jean Charles Sanchez
CEO
jean-charles.sanchez@abcdx.ch



Vuk Vegezti
CBO
vuk.vegezti@abcdx.ch

Category: Brain Health; Clinical Trials; Diagnostics and Personalized Medicine; Digital Health

ABCDx is at the forefront of revolutionizing brain injury diagnostics through their patented suite of blood-based biomarker tests, delivering rapid and non-invasively diagnosing of critical conditions including Large Vessel Occlusion (LVO), Ischemic vs. Hemorrhagic strokes, and Traumatic Brain Injury (TBI). Their flagship product, LVOCheck, is uniquely designed for use at the point of care. In ambulances, at ERs and in hospitals. LVO rapidly analyzes blood-based markers delivering results in minutes not hours resulting in the difference between recovery and long-term disability for patients.

Actome

Freiburg, Germany
www.actome.de



Csaba Jeney
CEO
csaba.jeney@actome.de

Category: Biotechnology; Diagnostics and Personalized Medicine; Oncology

Actome dedicates its efforts to the research, development, and commercialization of its outstanding proteomics tool called PICO, which caters to R&D, biotech, and pharmaceutical sectors. Their flagship developments include highly sensitive, absolute quantitative and multiplex targeted proteomics accessing complete cellular pathways and including as small samples as a single cell. Their focus extends beyond R&D, aiming to leverage these tools for diagnostic purposes, particularly in the oncology, immunology (CAR-cell therapies), and stem cell fields. They concentrate initially on areas such as signal transduction, offering superior alternatives to existing proteomics technologies, and advancing high-end diagnostics. To facilitate the seamless translation of scientific breakthroughs into clinical applications, they collaborate with prominent research institutions and biopharmaceutical companies, expediting the integration of scientific discoveries into practical healthcare solutions.

Akara

Dublin, Ireland
www.akara.ai



Connor McGinn
CEO
conor.mcgin@akara.ai



Niamh Donnelly
Chief Robotics Officer
niamh.donnelly@akara.ai

Category: Biotechnology; Digital Health

Akara develops AI powered robots and IoT technology to help hospitals and ambulatory services centres (ASCs) increase utilization of their operating rooms. Their technology does three things: (1) reduce the time and staff needed to clean the OR between cases, (2) collect better quality room utilization data than is possible from the EHR, and (3) prevent late arrivals to OR through automated real-time alerts. They are a spin-out from a top European University and have a patented, clinically validated, market ready product (TRL 7/8) with paying customers in 2 international countries (UK and Ireland). They are currently in the process of their first US sales, and have recently signed a MoU with the number 1 ranked ASC in the US. They also recently joined Techstars Healthcare LA that has a partnership with Cedars Sinai and UCI Health.

Augmedit

The Netherlands
www.augmedit.com



Claartje Yama
Co-Founder & CEO
claartje@augmedit.com

Category: Biotechnology; Diagnostics and Personalized Medicine;
Augmented Reality

Augmedit has developed a pioneering cloud-based Augmented Reality (AR) software, enhanced with Artificial Intelligence (AI), designed specifically for the surgical field. This innovative software transforms MRI or CT scans into detailed holograms, with AI algorithms automatically segmenting crucial anatomical structures for precision. These holograms are accessible via web platforms, Augmented Reality glasses, and a dedicated patient app, offering a versatile range of viewing options. Currently, their software is commercially available in the European Union, where it serves a vital role in surgical planning, medical training, and patient education. It has been adopted by prestigious medical institutions across the Netherlands, Switzerland, France, and the Czech Republic, underscoring its acceptance and utility in diverse healthcare environments. Their upcoming intraoperative guidance module, aimed at enhancing the accuracy of drain placements in neurosurgery, is set to launch in the European market this summer.

Bluedrop Medical

Galway, Ireland
www.bluedropmedical.com



Chris Murray
CEO
chris@bluedropmedical.com

Category: Digital Health, Medical Hardware, Diabetes

Bluedrop Medical is an early commercial stage company that uses remote patient monitoring and AI to predict and prevent diabetic foot ulcers - a 100k amputation, \$17B problem in the US. Their patented, FDA compliant, device takes the form of a standard home weight scale but is embedded with a proprietary array of 700+ temperature and image sensors. It captures visual and thermal data in a 30 second scan, which is sent to the cloud for analysis by their internal, AI augmented, monitoring team. If they see something, they reach out to the patient or provider with simple steps to prevent the ulcer. The techniques they use have been shown to prevent 70% of foot ulcers in 3 clinical trials, and are recommended by international clinical guidelines. In a 2023 study, 91% of patients were fully compliant to recommended use of Bluedrop's device. The company completed FDA compliance in 2023, and currently has 2 active commercial (paid) pilots in the US, with a further pilot with one of the largest payer/provider groups in the US to start next month. The company is raising a \$20M round, of which \$10M has already been secured.

Celtic Biotech

Dublin, Ireland
www.celticbiotech.com



Paul Reid
Co-Founder & CEO
paul.reid@celticbiotech.com



John Reid
Co-Founder & COD
john.reid@celticbiotech.com

Category: Biomanufacturing; Biotechnology; Clinical Trials; Oncology;
Rare Diseases

Celtic Biotech's novel biologic, CB-24, is directed at NSCLC utilizing proteins isolated from South American rattlesnake venom. A mono-or combination therapy, it has undergone evaluation by MD Anderson and the NIH/NCI. This anti-cancer agent targets nicotinic receptors on a broad range of solid tumors. Bioassay development to commence in the near future with the Broadstone Institute (USA). The results of Celtic Biotech's Phase I trials were presented at the American Association of Cancer Research.

Immunetep

Cantanhede, Portugal
www.immunetep.com



Bruno Santos
CEO
bruno.santos@immunetep.com

Category: Diagnostics and Personalized Medicine

Immunetep develops anti-bacterial immunotherapies. Their first product is Paragon Novel Vaccine (PNV). The first multi-bacterial vaccine, going into clinical trials which targets 5 different bacteria, with its groundbreaking approach of targeting the bacterial factor that is inhibiting the immune system to control the infection. PNV will replace the current pneumococcal vaccines as it has much wider coverage. It is protected by robust IP.

INBRAIN Neuroelectronics

Barcelona, Spain
www.inbrain-neuroelectronics.com



Carolina Aguilar
Co-Founder & CEO
caguilar@inbrain-
neuroelectronics.com

Category: Brain Health; Digital Health

Founded in 2020 as a spin-off from Graphene Flagship (1B EU program), INBRAIN Neuroelectronics is using graphene to drive highly targeted neuro and bioelectronic applications. Graphene brings high density precision and unparalleled resolution compared to metals like platinum and iridium. They have a strategic bioelectronic collaboration with Merck in very large pharma style indications such as anti-inflammation. Their graphene BCI cortical module just got MHRA approval for first in human and they are currently recruiting the first patient. Additionally they got FDA breakthrough designation for the implantable platform in movement control in Parkinson's disease. They are also focused on epileptic seizure detection and control. A QMS is in place with their ISO 13485 both for development and manufacturing of our graphene semiconductors technology. They have 19 patent applications with 5 grantings and they just signed a lead investor term sheet for their Series B round of €55M.

Ligence

Vilnius, Lithuania
www.ligence.io



Justinas Balčiūnas
COO
j.balciunas@ligence.io



Simas Tataris
CTO
s.tataris@ligence.io

Category: Diagnostics and Personalized Medicine; Digital Health

Ligence Heart is a patented AI platform with automated echocardiography interpretations and reporting, saving 50% of examination time, enhancing overall accuracy, and unlocking \$2M value per clinician yearly. It is CE marked under MDR and sold in Europe, FDA approval is expected by the end of 2024. They are in U.S. clinical trials at numerous university hospitals: Johns Hopkins, Yale and Northwestern. Integration with a large US based PACS provider was tested and sales are foreseen after FDA approval. Even without FDA approval, Ligence has been acquired for research purposes or testing technical integration capabilities, with most of these entities aiming to buy clinical licenses once the product passes FDA. They are in collaboration with a top 5 largest global ultrasound hardware manufacturer with an aim to use Ligence's AI tool to empower their competitive edge.

Luminate Medical

Galway, Ireland
www.luminatemed.com



Aaron Hannon
CEO
aaron.hannon@luminatemed.com



Cathy O'Boyle
Commercial Operations Executive
cathy.oboyle@luminatemed.com

Netris Pharma

Lyon, France
www.netrispharma.com



Christophe Guichard
CFO
christopheguichard@netri
spharma.com

PEPTOMYC

Barcelona, Spain
www.peptomyc.com



Joerg Klumbis
CFO
jklumbis@peptomyc.com



Marie-Eve Beaulieu
Co-Founder &
Chief Scientific Officer
mbeaulieu@peptomyc.com

Category: Oncology, Hair Loss Therapy

Luminate Medical is on a mission to change the way we experience cancer care. They design and build products which revolutionize the patient experience of cancer treatment. They're currently building our flagship product Lily, a wearable medical device to reduce hair loss caused by chemotherapy, and Lilac, our next-in-portfolio product to reduce peripheral nerve damage caused by chemotherapy.

Category: Biotechnology

Netris is an advanced clinical stage biopharmaceutical company, developing a novel solution targeting resistance to chemotherapies and immunotherapies in oncology. Their lead product is a monoclonal antibody which is currently in 5, phase 2 clinical trials. Their target is to enter the market in 3-4 years. They recently obtained IND from the FDA to launch a clinical study in the U.S. They are located at Centre Léon Bérard, the 2nd largest comprehensive cancer center in France.

Category: Oncology

Peptomyc is revolutionizing cancer treatment: they are the only company that uses mini-protein therapeutics to directly inhibit MYC - the central engine for cancer proliferation, survival, and resistance to treatment, deregulated in at least 70% of all cancers. Doing so, Peptomyc offers a foundational treatment to any cancer patient with abnormal MYC activity, improving patients' survival and quality of life. After a successful phase I trial in all-comer solid tumors (results published in Nature Medicine in Feb 2024), Peptomyc has initiated in 2023 a phase Ib trial in metastatic pancreatic cancer (mPDAC) to assess safety and efficacy in combination with the standard of care (SOC), and is boosting its pipeline - based on 11 patent families so far - and a commercial-ready manufacturing process that will sustain the scale up phase of the product.

SentryX

Utrecht, Netherlands
www.sentryx.nl



Floris Van Tol
Medical Scientist
floris@sentryx.nl

Category: Biomanufacturing; Biotechnology; Clinical Trials

SentryX is a clinical stage biopharmaceutical company developing implantable anesthetics: a revolutionary, non-opioid, localized approach to the treatment of acute pain after major surgery. Founded by entrepreneur Bas Oosterman and spine surgeon Jorrit-Jan Verlaan, SentryX's patented product, BR-003, is designed for co-implantation with surgical screws during spine fixation surgery. This proprietary lead product combines unique smart biomaterials with bupivacaine, an approved and widely used local pain blocker. The first-in-human clinical trial for BR-003 is nearing completion, demonstrating a 52% decrease in opioid consumption and a 36% reduction in pain during the critical first three days following spine fixation surgery. The company is preparing a single pivotal (Phase III) trial and the scaling up of its manufacturing capabilities. The results of the single pivotal trial, which will involve 200 patients across 10-15 sites in Europe, are expected in 2028 and will form the basis for an accelerated application for market approval in Europe and the US (MAA/NDA).

Uromems

Eybens, France
www.uromems.com



Hamid Lamroui
Co-Founder & CEO
hamid.lamroui@uromems.com

Category: Clinical Trials; Diagnostics and Personalized Medicine; Digital Health

Uromems has developed the first connected Artificial Urinary Sphincter (AUS), an active implantable medical device designed to treat severe Stress Urinary Incontinence (SUI) in men & women. Its breakthrough device solves all limitations of existing ones. UroActive™ is a Class III implantable medical device, consisting of a cuff that is implanted around the urethra (or the bladder neck in women) and a communicating implantable control unit, which contains the electronics, a battery, and a unique mechatronic fluidic system that inflates and deflates the cuff, thus closing or opening the urethral canal. They work closely with health authorities (FDA through the SteP Program) for their clinical development, over 60 international KOLS and with experts for their reimbursement strategy. They are currently raising a €60m Series C, €45m committed. They are presently launching their pivotal trials.



Agnès Dimey
CFO
agnès.dimey@uromems.com

Vitalera

Barcelona, Spain
www.humanicare.com



Nuria Pastor
Co-Founder & CEO
nuria.pastor@humanicare.com

Category: Digital Health

Vitalera offers a unique AI-based SaaS platform that is device-agnostic and pathology-independent, enabling remote patient monitoring across various conditions. Patients simply need to scan with a photo the screen of any medical device (regardless of brand and age), and vitalera instantly analyzes the vital signs and sends them directly to the patient's healthcare professionals. This technology significantly simplifies the integration process that often complicates remote monitoring solutions, streamlining operations and enhancing data collection efficiency in clinical environments such as hospitals, insurance, and nursing homes, and has been implemented in more than 20 healthcare centers including the BIMC (Harvard Medical School).



3 Meet the Team



Jean-David Malo
Director of the European Innovation
Council and SMEs Executive Agency
(EISMEA)
Jean-David.MALO@ec.europa.eu



Jillian Manus
Managing Partner, Structure Capital
and EIC US Venture Advisor
Jillian@structure.vc



Gerard de Graaf
Senior Envoy for Digital to the
U.S. and Head of the EU Office in
San Francisco
Gerard.DE-GRAAF@ec.europa.eu



Joanna Smolinska
Counsellor for Digital to the U.S. and
Deputy Head of the EU Office in San
Francisco
joanna.SMOLINSKA@ec.europa.eu



Catherine Frideres
Project Director, EIC Soft-landing
Programme team
catherine.frideres@pwc.lu



Manuel Mendigutia
Senior adviser of the European
Innovation Council and SMEs
Executive Agency (EISMEA)
manuel.MENDIGUTIA@ec.europa.eu

4 ■ Meet the Partners



Jillian Manus, Managing Partner, Structure Capital

Jillian Manus is Managing Partner of an early-stage Silicon Valley venture fund, Structure Capital. Branded “Architects of the Zero Waste Economy,” they invest in underutilized assets and excess capacity. She was named one of the top 25 early-stage Female Investors by Business Insider in 2021. She serves on numerous corporate and non-profit boards that include: Stanford University School of Medicine Board of Fellows, NASDAQ Entrepreneurial Center Board of Directors, NYU Tisch School of the Arts, Communities in Schools, Safe and Sound, & Shift. Prior to Structure Capital, she served as Co- Director of TMT for Credit Suisse Zurich, and Director of Development for Universal and Warner Bros., she was Associate Publisher of the national publication Upside, reporting on the financial strategies of the technology industry. Ms. Manus was also the Founder of Broad Strategy and Global Goal Management, Inc. A frequent global public speaker, she provides business and political commentary across numerous media platforms, including CNBC, Bloomberg and CNN. She also co-hosts the business podcast “The Pitch.”



Stanford School of Medicine in Palo Alto

A leader in the biomedical revolution, Stanford Medicine has a long tradition of leadership in pioneering research, creative teaching protocols and effective clinical therapies. Its close proximity to the resources of the university — including the Schools of Business, Law, Humanities and Sciences, and Engineering, seamless relationship with our affiliated adult and children’s hospitals, and ongoing associations with the entrepreneurial endeavors of Silicon Valley, makes this institution uniquely positioned to accelerate the pace at which new knowledge is translated into tangible health benefits.



Nasdaq Entrepreneurial Center San Francisco

The Nasdaq Entrepreneurial Center is a non-profit organisation that is building a better path for entrepreneurs worldwide. Established in 2014 with support from the Nasdaq Educational Foundation, the Center serves entrepreneurs from around the world through events, education, and mentorship. The Center’s Innovation Hub is where entrepreneurs take hands-on classes and workshops; drop in for mentoring or training sessions with founders and experts from a variety of industries; and enjoy the premium space with whiteboard walls with interactive webcasting for worldwide collaboration.



www.insead.edu

INSEAD - San Francisco Hub for Business Innovation

INSEAD has been a global leader in business education and research for six decades. They launched the world's first 10-month MBA in Fontainebleau, France, in 1959. In 2000, they opened the Asia Campus in Singapore and became the first business school with campuses on two continents. The Middle East Campus in Abu Dhabi opened in 2010 with innovation in focus. INSEAD San Francisco Hub for Business Innovation in North America, which opened in 2020, is a space to forge connections and build on 60 years of excellence. INSEAD embraces global citizenship, and each location draws inspiration, expertise, and connections to shape the future of business. Like the Bay Area, the Hub embodies the region's tenacity, innovation, and vibrant energy. INSEAD's mission is to bring together people, cultures, and ideas to develop responsible leaders who transform business and society.



www.bayareacouncil.org

Bay Area Council

The Bay Area Council has been at the intersection of business and civic leadership, shaping the future of the Bay Area since 1945. Today, its vision is to make the Bay Area the world's best place to live and work. More than 330 of the largest employers in the region are members. The Council's Economic Institute focuses on issues relating to technology, innovation and global business, while its science affiliate BASIC (the Bay Area Science and Innovation Consortium) connects leaders on the region's technology and life science research community.



www.commonwealthclub.org

Commonwealth Club World Affairs of California

The Commonwealth Club World Affairs of California is the nation's oldest and largest public affairs forum. Every year, they present hundreds of forums on topics ranging across politics, culture, society, artificial intelligence and the economy. The Club is headquartered in San Francisco, with regular events in San Francisco as well as in Silicon Valley, the East Bay and the North Bay. The mission of Commonwealth Club World Affairs is to be the leading national forum open to all for the impartial discussion of public issues important to the membership, community and nation.



Notes



Notes




Notes

■ Notes

European
Innovation
Council



EIC USA
Soft-landing
Programme



eic.ec.europa.eu